Dr. Matt Coffey reports
ONCOLYTICS BIOTECH ANNOUNCES LISTING ON NASDAQ CAPITAL MARKET
Oncolytics Biotech Inc.'s shares of common stock were approved for listing on the Nasdaq Capital Market. Oncolytics Biotech's common stock will commence trading on the Nasdaq Capital Market today, June 1, 2018, under the symbol ONCY.
"Listing on Nasdaq, a premier U.S. stock exchange, represents another significant milestone for Oncolytics and our shareholders," said Dr. Matt Coffey, president and chief executive officer of Oncolytics Biotech. "As a Nasdaq-listed company, we expect to have the opportunity to broaden our exposure to biotech-focused institutional investors, diversify our shareholder base, expand our access to capital and increase the liquidity of our shares."
Oncolytics's common stock will continue to trade on the Toronto Stock Exchange (TSX) under the trading symbol ONC.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.